The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases
Abstract
Compared to intravitreal injection, subretinal injection has more direct effects on the targeting cells in the subretinal space, which provides a new therapeutic method for vitreoretinal diseases, especially when gene therapy and/or cell therapy is involved. To date, subretinal delivery has been widely applied by scientists and clinicians as a more precise and efficient route of ocular drug delivery for gene therapies and cell therapies including stem cells in many degenerative vitreoretinal diseases, such as retinitis pigmentosa, age-related macular degeneration, and Leber's congenital amaurosis. However, clinicians should be aware of adverse events and possible complications when performing subretinal delivery. In the present review, the subretinal injection used in vitreoretinal diseases for basic research and clinical trials is summarized and described. Different methods of subretinal delivery, as well as its benefits and challenges, are also briefly introduced.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subretinal drug is administered between the retinal photoreceptor cells and the RPE layer, requires less vector than intravitreal injections to achieve a therapeutic effect on the retina.127”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [127]
In the citing paper
“Despite these advantages, intravitreal injections also carry risks of adverse reactions, including inflammation, endophthalmitis, increased intraocular pressure, retinal detachment, hemorrhage, and cataracts, and due to the repeated use of these injections in various treatments, patient compliance can become an issue.119,127,129”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [127]
In the citing paper
“However, this route of administration can further damage an already damaged retina, leading to retinal or RPE detachment from underlying layers, hemorrhage, and changes in retinal pigmentation.35,127,128”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [127]
In the citing paper
“Most gene therapy viral vectors given intravitreally, fail to adequately transduce photoreceptors and RPE, due to the inner limiting membrane that divides the vitreous from the retina.1,15,119,127”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [127]
Citations
Cites
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Embryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Ghasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Ocular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 890
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Cited by
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
“, via subretinal injection) can circumvent biological barriers and enable access to certain important cell populations (Bottros and Christo, 2014; Peng et al., 2017).”
BackgroundVarela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A., & Otero-Espinar, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 354
“Subretinal delivery can also be used for stem cell transplantation in ocular degenerative diseases, which was reported in vivo studies and aimed at clinical applications [224].”
BackgroundMethodInfluentialMammalian Near-Infrared Image Vision through Injectable and Self-Powered Retinal Nanoantennae
Ma, Y., Bao, J., Zhang, Y., Li, Z., Zhou, X., Wan, C., Huang, L., Zhao, Y., Han, G., & Xue, T. (2019) · Cell · doi:10.1016/j.cell.2019.01.038 · Cited by 292
“As sub-retinal injections are a commonly used ophthalmological practice in animals and humans (Hauswirth et al., 2008; Peng et al., 2017), our pbUCNPs were dissolved in PBS and then injected into the sub-retinal space in the eyes of mice.”
The effects of PEGylation on LNP based mRNA delivery to the eye
Ryals, R. C., Patel, S., Acosta, C., McKinney, M., Pennesi, M. E., & Sahay, G. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241006 · Cited by 194
“Specific to treating the retina, clinicians and scientists are in much debate over the visual impact of detaching the fovea and/or a fragile degenerating retina during a subretinal injection [6].”
BackgroundGasparini, S. J., Llonch, S., Borsch, O., & Ader, M. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.11.001 · Cited by 186
Metadata
- Authors
- Peng, Y., Tang, L., & Zhou, Y.
- Affiliations
- Central South University (CN)
- Venue
- Ophthalmic Research
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 58
- Issue
- 4
- Pages
- 217-226
- ISSN
- 0030-3747 (ISSN-L)
- 1423-0259
- OpenAlex
- W2752393253
- Cited by
- 175
- References
- 108
- Citations by year
- 2026: 13 · 2025: 25 · 2024: 27 · 2023: 21 · 2022: 29 · 2021: 24 · 2020: 15 · 2019: 14 · 2018: 6
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Ophthalmic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- subretinal injection, ocular drug delivery, vitreoretinal disease, gene therapy, cell therapy, stem cell therapy, retinitis pigmentosa, age-related macular degeneration, Leber congenital amaurosis, degenerative retinal diseases, injection complications
- MeSH terms
- Animals, Genetic Vectors, Humans, Injections, Retina, Retinal Diseases, Genetic Therapy, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases. https://app.cochat.ai/papers/10.1159/000479157
- The paper
- Peng, Y., Tang, L., & Zhou, Y. (2017). Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases. Ophthalmic Research. https://doi.org/10.1159/000479157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.